ATLAB Pharma SAS-Product Pipeline Review-2015

ATLAB Pharma SAS-Product Pipeline Review-2015

  • Products Id :- GMDHC07125CDB
  • |
  • Pages: 22
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

ATLAB Pharma SAS-Product Pipeline Review-2015


Global Markets Direct's, 'ATLAB Pharma SAS-Product Pipeline Review-2015', provides an overview of the ATLAB Pharma SAS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ATLAB Pharma SAS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of ATLAB Pharma SAS including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of ATLAB Pharma SAS's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the ATLAB Pharma SAS's pipeline products

Reasons To Buy

Evaluate ATLAB Pharma SAS's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of ATLAB Pharma SAS in its therapy areas of focus

Identify new drug targets and therapeutic classes in the ATLAB Pharma SAS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of ATLAB Pharma SAS and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of ATLAB Pharma SAS

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of ATLAB Pharma SAS and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

ATLAB Pharma SAS Snapshot 4

ATLAB Pharma SAS Overview 4

Key Information 4

Key Facts 4

ATLAB Pharma SAS-Research and Development Overview 5

Key Therapeutic Areas 5

ATLAB Pharma SAS-Pipeline Review 6

Pipeline Products by Stage of Development 6

Pipeline Products-Monotherapy 7

ATLAB Pharma SAS-Pipeline Products Glance 8

ATLAB Pharma SAS-Clinical Stage Pipeline Products 8

Phase II Products/Combination Treatment Modalities 8

ATLAB Pharma SAS-Early Stage Pipeline Products 9

Preclinical Products/Combination Treatment Modalities 9

ATLAB Pharma SAS-Drug Profiles 10

ATL-101 10

Product Description 10

Mechanism of Action 10

R&D Progress 10

ATL-201 12

Product Description 12

Mechanism of Action 12

R&D Progress 12

ATL-301 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

ATL-302 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

ATLAB Pharma SAS-Pipeline Analysis 15

ATLAB Pharma SAS-Pipeline Products by Target 15

ATLAB Pharma SAS-Pipeline Products by Route of Administration 16

ATLAB Pharma SAS-Pipeline Products by Molecule Type 17

ATLAB Pharma SAS-Pipeline Products by Mechanism of Action 18

ATLAB Pharma SAS-Recent Pipeline Updates 19

ATLAB Pharma SAS-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Appendix 21

Methodology 21

Coverage 21

Secondary Research 21

Primary Research 21

Expert Panel Validation 21

Contact Us 21

Disclaimer 22

List of Tables

ATLAB Pharma SAS, Key Information 4

ATLAB Pharma SAS, Key Facts 4

ATLAB Pharma SAS-Pipeline by Indication, 2015 5

ATLAB Pharma SAS-Pipeline by Stage of Development, 2015 6

ATLAB Pharma SAS-Monotherapy Products in Pipeline, 2015 7

ATLAB Pharma SAS-Phase II, 2015 8

ATLAB Pharma SAS-Preclinical, 2015 9

ATLAB Pharma SAS-Pipeline by Target, 2015 15

ATLAB Pharma SAS-Pipeline by Route of Administration, 2015 16

ATLAB Pharma SAS-Pipeline by Molecule Type, 2015 17

ATLAB Pharma SAS-Pipeline Products by Mechanism of Action, 2015 18

ATLAB Pharma SAS-Recent Pipeline Updates, 2015 19

ATLAB Pharma SAS, Other Locations 20

List of Figures

ATLAB Pharma SAS-Pipeline by Top 10 Indication, 2015 5

ATLAB Pharma SAS-Pipeline by Stage of Development, 2015 6

ATLAB Pharma SAS-Monotherapy Products in Pipeline, 2015 7

ATLAB Pharma SAS-Pipeline by Top 10 Target, 2015 15

ATLAB Pharma SAS-Pipeline by Top 10 Molecule Type, 2015 17

ATLAB Pharma SAS-Pipeline Products by Top 10 Mechanism of Action, 2015 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of ATLAB Pharma SAS; ATLAB Pharma SAS - Key Therapeutics; ATLAB Pharma SAS - Pipeline Overview and Promising Molecules; ATLAB Pharma SAS - News; ATLAB Pharma SAS - Latest Updates; ATLAB Pharma SAS - Pipeline; ATLAB Pharma SAS - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 97500
Site License
USD 3000 INR 195000
Corporate User License
USD 4500 INR 292500



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]